If you’ve heard about Spravato and wondered whether it could become a problem, you’re asking the right question.
The short answer: Spravato does have abuse potential, but addiction in a supervised clinical setting is rare. It contains esketamine, a controlled substance related to ketamine. That fact alone raises understandable concerns. But the way clinics administer and monitor it makes a significant difference.
Here’s what you actually need to know.
What Is Spravato?
Spravato is an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It contains esketamine, a derivative of ketamine. The FDA classifies it as a Schedule III controlled substance.
Unlike antidepressants you take at home, patients use Spravato only in a certified healthcare setting. A provider must supervise each session. That supervised model exists specifically because of the drug’s potential for misuse.
Practices like Autumn Leaves Psychiatry follow strict REMS (Risk Evaluation and Mitigation Strategy) protocols required by the FDA. Patients cannot take the medication home. That matters when evaluating addiction risk.
Does Spravato Cause Physical Dependence?
Yes, the body can adapt to esketamine over time. Repeated use may lead to physical dependence. That’s a fair concern and worth taking seriously.
But physical dependence and “being addicted” are not the same thing. A lot of people confuse the two. Addiction means compulsive, uncontrolled use that keeps happening even when it’s causing real harm. Physical dependence just means the body has adjusted to a substance, which happens with plenty of common medications, including certain antidepressants and blood pressure drugs.
In clinical trials, patients using Spravato under medical supervision showed low rates of dependence. That’s not a coincidence. The structured dosing schedule gives patients far less opportunity to misuse the drug than they would have with an unmonitored substance.
How Is Supervised Use Different From Recreational Ketamine Use?
Recreational ketamine use looks very different from clinical Spravato treatment.
Recreational users often take much higher doses. They use it repeatedly without medical oversight. They seek the dissociative “high” the drug produces. That pattern creates a real risk of psychological dependence.
Spravato treatment involves lower, carefully controlled doses. Providers monitor patients for at least 2 hours after each administration. Sessions happen on a defined schedule, typically twice a week for the first month and then tapering. Patients have no access to the medication outside of those sessions.
The team at Autumn Leaves Psychiatry screens every patient before starting Spravato. A history of substance use disorder is an important factor in that evaluation. Patients with active addiction or a recent history of substance misuse may not qualify as candidates.
What Are the Side Effects Related to Abuse Potential?
Spravato can produce dissociation, sedation, dizziness, and perceptual disturbances during and shortly after administration. These effects are why patients cannot drive or use heavy machinery on treatment days.
Some patients find these sensations uncomfortable. Others do not. In either case, the clinical setting limits the ability to seek out those effects for non-medical purposes.
Post-approval safety monitoring has not shown widespread addiction problems among Spravato patients in certified programs. The FDA continues to require the REMS program as a precaution.
Who Should Not Use Spravato?
Spravato is not appropriate for everyone. Providers typically rule out patients who have:
- A personal or family history of psychosis
- Active or recent substance use disorder
- Certain cardiovascular conditions
- Known hypersensitivity to esketamine or ketamine
A thorough evaluation at a practice like Autumn Leaves Psychiatry helps determine whether Spravato is a safe and appropriate option.
The Bottom Line
Spravato carries a real abuse potential because of its classification as a controlled substance. That concern is legitimate and worth discussing openly with your provider.
But addiction from supervised clinical use is uncommon. The REMS program, the in-office-only administration, and the structured dosing schedule all exist to protect patients from misuse. For many people with treatment-resistant depression, Spravato represents a meaningful option when other treatments have failed.
The goal is never to dismiss the risk. It’s to put the risk in a proper context so patients can make informed decisions.
Take the Next Step
If you want to learn more about whether Spravato is right for you, start with an honest conversation with a qualified provider. You can contact Autumn Leaves Psychiatry to schedule a consultation. They will walk you through the evaluation process and answer your questions without pressure.